Research ExplorerPublicationsAsymmetrical dimethylarginine (ADMA) and coronary endothelia...

Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia.

Standard

Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. / Maas, Renke; Quitzau, Kurt; Schwedhelm, Edzard; Spieker, Lukas; Rafflenbeul, Wolf; Steenpass, Anna; Lüscher, Thomas F; Böger, Rainer.

In: ATHEROSCLEROSIS, Vol. 191, No. 1, 1, 2007, p. 211-219.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Maas, R, Quitzau, K, Schwedhelm, E, Spieker, L, Rafflenbeul, W, Steenpass, A, Lüscher, TF & Böger, R 2007, 'Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia.', ATHEROSCLEROSIS, vol. 191, no. 1, 1, pp. 211-219. <http://www.ncbi.nlm.nih.gov/pubmed/16828780?dopt=Citation>

APA

Maas, R., Quitzau, K., Schwedhelm, E., Spieker, L., Rafflenbeul, W., Steenpass, A., Lüscher, T. F., & Böger, R. (2007). Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. ATHEROSCLEROSIS, 191(1), 211-219. [1]. http://www.ncbi.nlm.nih.gov/pubmed/16828780?dopt=Citation

Vancouver

Maas R, Quitzau K, Schwedhelm E, Spieker L, Rafflenbeul W, Steenpass A et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. ATHEROSCLEROSIS. 2007;191(1):211-219. 1.

Bibtex

@article{35cf8183410d4e5db462bb077939c5bf,
title = "Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia.",
abstract = "OBJECTIVE: To investigate the association of the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and coronary endothelial function. METHODS AND RESULTS: In 289 patients with coronary artery disease we assessed coronary endothelium-dependent and -independent vascular responses to intracoronary infusion of acetylcholine, adenosine, and nitroglycerin, respectively, and determined plasma ADMA and l-arginine concentrations by HPLC. After 6 months of treatment with either cerivastatin, nifedipine, cerivastatin+nifedipine, or placebo, coronary vascular function testing as well as ADMA and l-arginine determinations were repeated. We observed no correlation of plasma ADMA or l-arginine concentration and coronary response to acetylcholine, adenosine or nitroglycerin baseline, and no correlation of changes of ADMA or l-arginine plasma concentration with changes in coronary function (all r and rho0.05). CONCLUSION: At physiological plasma concentrations ADMA appears to have only little impact on coronary endothelial function.",
author = "Renke Maas and Kurt Quitzau and Edzard Schwedhelm and Lukas Spieker and Wolf Rafflenbeul and Anna Steenpass and L{\"u}scher, {Thomas F} and Rainer B{\"o}ger",
year = "2007",
language = "Deutsch",
volume = "191",
pages = "211--219",
journal = "ATHEROSCLEROSIS",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia.

AU - Maas, Renke

AU - Quitzau, Kurt

AU - Schwedhelm, Edzard

AU - Spieker, Lukas

AU - Rafflenbeul, Wolf

AU - Steenpass, Anna

AU - Lüscher, Thomas F

AU - Böger, Rainer

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: To investigate the association of the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and coronary endothelial function. METHODS AND RESULTS: In 289 patients with coronary artery disease we assessed coronary endothelium-dependent and -independent vascular responses to intracoronary infusion of acetylcholine, adenosine, and nitroglycerin, respectively, and determined plasma ADMA and l-arginine concentrations by HPLC. After 6 months of treatment with either cerivastatin, nifedipine, cerivastatin+nifedipine, or placebo, coronary vascular function testing as well as ADMA and l-arginine determinations were repeated. We observed no correlation of plasma ADMA or l-arginine concentration and coronary response to acetylcholine, adenosine or nitroglycerin baseline, and no correlation of changes of ADMA or l-arginine plasma concentration with changes in coronary function (all r and rho0.05). CONCLUSION: At physiological plasma concentrations ADMA appears to have only little impact on coronary endothelial function.

AB - OBJECTIVE: To investigate the association of the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and coronary endothelial function. METHODS AND RESULTS: In 289 patients with coronary artery disease we assessed coronary endothelium-dependent and -independent vascular responses to intracoronary infusion of acetylcholine, adenosine, and nitroglycerin, respectively, and determined plasma ADMA and l-arginine concentrations by HPLC. After 6 months of treatment with either cerivastatin, nifedipine, cerivastatin+nifedipine, or placebo, coronary vascular function testing as well as ADMA and l-arginine determinations were repeated. We observed no correlation of plasma ADMA or l-arginine concentration and coronary response to acetylcholine, adenosine or nitroglycerin baseline, and no correlation of changes of ADMA or l-arginine plasma concentration with changes in coronary function (all r and rho0.05). CONCLUSION: At physiological plasma concentrations ADMA appears to have only little impact on coronary endothelial function.

M3 - SCORING: Zeitschriftenaufsatz

VL - 191

SP - 211

EP - 219

JO - ATHEROSCLEROSIS

JF - ATHEROSCLEROSIS

SN - 0021-9150

IS - 1

M1 - 1

ER -